143 related articles for article (PubMed ID: 26774883)
61. Diagnostic and prognostic values of FDG-PET in patients with non-small cell lung cancer.
Abe K; Baba S; Kaneko K; Isoda T; Yabuuchi H; Sasaki M; Sakai S; Yoshino I; Honda H
Clin Imaging; 2009; 33(2):90-5. PubMed ID: 19237050
[TBL] [Abstract][Full Text] [Related]
62. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Scheiderbauer J; Budach W; Kotzerke J; Bares R
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):54-9. PubMed ID: 16896660
[TBL] [Abstract][Full Text] [Related]
63. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
[TBL] [Abstract][Full Text] [Related]
64. PET scan 18F-fluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer.
Nair VS; Barnett PG; Ananth L; Gould MK;
Chest; 2010 May; 137(5):1150-6. PubMed ID: 20038738
[TBL] [Abstract][Full Text] [Related]
65. Clinical significance of (18)F-FDG uptake by N2 lymph nodes in patients with resected stage IIIA N2 non-small-cell lung cancer: a retrospective study.
Na II; Cheon GJ; Choe DH; Byun BH; Kang HJ; Koh JS; Park JH; Baek H; Ryoo BY; Lee JC; Yang SH
Lung Cancer; 2008 Apr; 60(1):69-74. PubMed ID: 18029051
[TBL] [Abstract][Full Text] [Related]
66. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer.
Hoopes DJ; Tann M; Fletcher JW; Forquer JA; Lin PF; Lo SS; Timmerman RD; McGarry RC
Lung Cancer; 2007 May; 56(2):229-34. PubMed ID: 17353064
[TBL] [Abstract][Full Text] [Related]
67. [Value of 18F-FDG PET in clinical staging of non-small-cell lung cancer].
Liu SW; Yu JM; Xing LG
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):626-9. PubMed ID: 15634527
[TBL] [Abstract][Full Text] [Related]
68. Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy.
Tanaka H; Hayashi S; Hoshi H
Asia Pac J Clin Oncol; 2016 Mar; 12(1):e113-7. PubMed ID: 24176011
[TBL] [Abstract][Full Text] [Related]
69. Quantitative modifications of TNM staging, clinical staging and therapeutic intent by FDG-PET/CT in patients with non small cell lung cancer scheduled for radiotherapy--a retrospective study.
Abramyuk A; Appold S; Zöphel K; Hietschold V; Baumann M; Abolmaali N
Lung Cancer; 2012 Nov; 78(2):148-52. PubMed ID: 22922126
[TBL] [Abstract][Full Text] [Related]
70. Prognostic impact of 18F-FDG uptake on PET in non-small cell lung cancer patients with postoperative recurrence following platinum-based chemotherapy.
Kaira K; Yamamoto N; Kenmotsu H; Murakami H; Ono A; Naito T; Endo M; Takahashi T
Respir Investig; 2014 Mar; 52(2):121-8. PubMed ID: 24636268
[TBL] [Abstract][Full Text] [Related]
71. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
Farrell MA; McAdams HP; Herndon JE; Patz EF
Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
[TBL] [Abstract][Full Text] [Related]
72. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy.
Pyka T; Bundschuh RA; Andratschke N; Mayer B; Specht HM; Papp L; Zsótér N; Essler M
Radiat Oncol; 2015 Apr; 10():100. PubMed ID: 25900186
[TBL] [Abstract][Full Text] [Related]
73. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy.
MacManus MP; Hicks RJ; Matthews JP; Hogg A; McKenzie AF; Wirth A; Ware RE; Ball DL
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):287-93. PubMed ID: 11380213
[TBL] [Abstract][Full Text] [Related]
74. Validation of Independent Prognostic Value of Asphericity of
Rogasch JMM; Furth C; Chibolela C; Hofheinz F; Ochsenreither S; Rückert JC; Neudecker J; Böhmer D; von Laffert M; Amthauer H; Frost N
Clin Lung Cancer; 2020 May; 21(3):264-272.e6. PubMed ID: 31839531
[TBL] [Abstract][Full Text] [Related]
75. N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT.
Ohno Y; Koyama H; Yoshikawa T; Nishio M; Aoyama N; Onishi Y; Takenaka D; Matsumoto S; Maniwa Y; Nishio W; Nishimura Y; Itoh T; Sugimura K
Radiology; 2011 Nov; 261(2):605-15. PubMed ID: 21926377
[TBL] [Abstract][Full Text] [Related]
76. Mediastinal staging in Non-Small-Cell Lung Carcinoma: computed tomography versus F-18-fluorodeoxyglucose positron-emission tomography and computed tomography.
Harders SW; Madsen HH; Hjorthaug K; Arveschoug AK; Rasmussen TR; Meldgaard P; Hoejbjerg JA; Pilegaard HK; Hager H; Rehling M; Rasmussen F
Cancer Imaging; 2014 Jun; 14(1):23. PubMed ID: 25608616
[TBL] [Abstract][Full Text] [Related]
77. The lung cancers: staging and response, CT,
Owens C; Hindocha S; Lee R; Millard T; Sharma B
Br J Radiol; 2023 Aug; 96(1148):20220339. PubMed ID: 37097296
[TBL] [Abstract][Full Text] [Related]
78. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging.
Antoch G; Stattaus J; Nemat AT; Marnitz S; Beyer T; Kuehl H; Bockisch A; Debatin JF; Freudenberg LS
Radiology; 2003 Nov; 229(2):526-33. PubMed ID: 14512512
[TBL] [Abstract][Full Text] [Related]
79. First-in-Humans PET Imaging of
Li X; Ye J; Wang J; Quan Z; Li G; Ma W; Zhang M; Yang W; Wang J; Ma T; Kang F; Wang J
J Nucl Med; 2023 Dec; 64(12):1880-1888. PubMed ID: 37827842
[TBL] [Abstract][Full Text] [Related]
80. Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
Kinoshita T; Fujii H; Hayashi Y; Kamiyama I; Ohtsuka T; Asamura H
Lung Cancer; 2016 Jan; 91():56-66. PubMed ID: 26711935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]